Ono Pharma Usa

Ono Pharma Usa company information, Employees & Contact Information

Explore related pages

Related company profiles:

ONO PHARMA USA is the US subsidiary of ONO PHARMACEUTICAL CO, LTD., an R&D-oriented pharmaceutical company founded in 1717, with headquarters in Osaka, Japan. For over 300 years, ONO has been committed to delivering novel medicines to patients with high unmet medical need. Our passion has led to first-in-class therapies including the world’s first chemically synthesized prostaglandins as well as nivolumab, the world’s first anti-PD-1 antibody. These drugs have changed the treatment paradigm and outlook for millions of people globally. Today, ONO has a growing pipeline of innovative therapeutics across four focus areas: oncology, immunology, neurology, and specialty medicine. ONO is committed to Challenging the Unknown, relentlessly pursuing research that will bring safe and effective solutions to more patients around the world. For information on our community guidelines, visit: http://bit.ly/43MdR0S

Company Details

Employees
101
Address
1 Main Street,
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Cambridge, Massachusetts
Looking for a particular Ono Pharma Usa employee's phone or email?

Ono Pharma Usa Questions

News

ONO Receives Highest A-List Rating in CDP 2024 Report for Climate Change and Water Security Efforts - ono-pharma.com

ONO Receives Highest A-List Rating in CDP 2024 Report for Climate Change and Water Security Efforts ono-pharma.com

Fierce Pharma Asia—Akeso bispecific's first survival readout; AstraZeneca's China probes; Ono's layoffs - Fierce Pharma

Fierce Pharma Asia—Akeso bispecific's first survival readout; AstraZeneca's China probes; Ono's layoffs Fierce Pharma

ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups - PR Newswire

ONO PHARMA USA Announces 2025 Golden Ticket CompetitionNow Accepting Applications from Innovative Startups PR Newswire

Ono's BMS-partnered oral gastric cancer drug tastes mid-stage success - FirstWord Pharma

Ono's BMS-partnered oral gastric cancer drug tastes mid-stage success FirstWord Pharma

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea - Business Wire

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea Business Wire

ONO Achieves Top 1% in S&P Sustainability Yearbook 2025 - ono-pharma.com

ONO Achieves Top 1% in S&P Sustainability Yearbook 2025 ono-pharma.com

Support for Assessing Therapeutic Efficacy in Patients with Inflammatory Bowel Disease through Unstructured Data in Electronic Health Records - NTT Data

Support for Assessing Therapeutic Efficacy in Patients with Inflammatory Bowel Disease through Unstructured Data in Electronic Health Records NTT Data

FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout - Fierce Pharma

FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout Fierce Pharma

Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics - Business Wire

Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics Business Wire

Ono bags Ionis' polycythaemia vera asset for $280M upfront - FirstWord Pharma

Ono bags Ionis' polycythaemia vera asset for $280M upfront FirstWord Pharma

Fierce Pharma Asia—TROP2 showdown; InnoCare, Zenas' $2B autoimmune deal; Lupin's US investment - Fierce Pharma

Fierce Pharma Asia—TROP2 showdown; InnoCare, Zenas' $2B autoimmune deal; Lupin's US investment Fierce Pharma

Ono wins FDA approval for TGCT treatment gained via Deciphera takeout - FirstWord Pharma

Ono wins FDA approval for TGCT treatment gained via Deciphera takeout FirstWord Pharma

ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan - ono-pharma.com

ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan ono-pharma.com

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) - Business Wire

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) Business Wire

Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal - Fierce Pharma

Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal Fierce Pharma

STORY02 | ONO Pharmaceutical’s corporate slogan: BREAK THROUGH" - ono-pharma.com

STORY02 | ONO Pharmaceutical’s corporate slogan: BREAK THROUGH" ono-pharma.com

Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod - Fierce Pharma

Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod Fierce Pharma

STORY01 | ONO Pharmaceutical’s corporate slogan: BREAK THROUGH" - ono-pharma.com

STORY01 | ONO Pharmaceutical’s corporate slogan: BREAK THROUGH" ono-pharma.com

Greetings | About | ONO PHARMACEUTICAL CO., LTD. - ono-pharma.com

Greetings | About | ONO PHARMACEUTICAL CO., LTD. ono-pharma.com

ONO Introduces Carbon Neutral City Gas - ono-pharma.com

ONO Introduces Carbon Neutral City Gas ono-pharma.com

Equillium's pivotal GvHD study of anti-CD6 antibody comes up short - FirstWord Pharma

Equillium's pivotal GvHD study of anti-CD6 antibody comes up short FirstWord Pharma

The top 10 biopharma M&A deals of 2024 - Fierce Pharma

The top 10 biopharma M&A deals of 2024 Fierce Pharma

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) - Business Wire

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) Business Wire

Japan's Ono pays $2.4B for Qinlock maker Deciphera as biotech readies another approval run - Fierce Pharma

Japan's Ono pays $2.4B for Qinlock maker Deciphera as biotech readies another approval run Fierce Pharma

Ono Acquires Deciphera Pharmaceuticals - Contract Pharma

Ono Acquires Deciphera Pharmaceuticals Contract Pharma

ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative Startups - PR Newswire

ONO PHARMA USA Announces 2024 Golden Ticket Competition Now Accepting Applications from Innovative Startups PR Newswire

Ono Pharmaceutical to Acquire Deciphera for $2.4B - Contract Pharma

Ono Pharmaceutical to Acquire Deciphera for $2.4B Contract Pharma

ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL - PR Newswire

ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL PR Newswire

ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs - PR Newswire

ONO PHARMA USA Announces 2023 Golden Ticket Competition in Partnership with LabCentral and MBC BioLabs PR Newswire

Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024 - Fierce Pharma

Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024 Fierce Pharma

AstraZeneca faces $278M Imfinzi patent infringement lawsuit from co-developer Ono - Fierce Pharma

AstraZeneca faces $278M Imfinzi patent infringement lawsuit from co-developer Ono Fierce Pharma

Ono, Admid Partner on Novel Antibody Drugs in Oncology - Contract Pharma

Ono, Admid Partner on Novel Antibody Drugs in Oncology Contract Pharma

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment - Targeted Oncology

PROSPECT Study of Tirabrutinib in R/R PCNSL Completes Part A Enrollment Targeted Oncology

Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas' gene therapy pact, new cell therapy site - Fierce Pharma

Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas' gene therapy pact, new cell therapy site Fierce Pharma

Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets - The AI Journal

Turbine Establishes Research Collaboration with Ono Pharmaceutical to Identify and Validate Novel Oncology Targets The AI Journal

Nobel laureate behind Bristol-Myers' I-O superstar Opdivo demands a bigger cut - Fierce Pharma

Nobel laureate behind Bristol-Myers' I-O superstar Opdivo demands a bigger cut Fierce Pharma

Japan cuts prices on BMS and Ono's Opdivo, Merck's Keytruda: report - Fierce Pharma

Japan cuts prices on BMS and Ono's Opdivo, Merck's Keytruda: report Fierce Pharma

Bristol-Myers partner Ono opens up Japanese front in Opdivo vs. Keytruda patent war - Fierce Pharma

Bristol-Myers partner Ono opens up Japanese front in Opdivo vs. Keytruda patent war Fierce Pharma

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) - Business Wire

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Business Wire

Price cuts in Japan make the country 'less predictable,' BIO official says - Fierce Pharma

Price cuts in Japan make the country 'less predictable,' BIO official says Fierce Pharma

Opdivo lifts Ono's fortunes once again with new Japanese approval in kidney cancer - Fierce Pharma

Opdivo lifts Ono's fortunes once again with new Japanese approval in kidney cancer Fierce Pharma

FiercePharmaAsia—PD-1 royalty dispute; Takeda Latam asset sale; Chinese genomics investor in U.S. - Fierce Pharma

FiercePharmaAsia—PD-1 royalty dispute; Takeda Latam asset sale; Chinese genomics investor in U.S. Fierce Pharma

Bristol Myers, AstraZeneca settle PD-1, CTLA-4 cancer immunotherapy patent suits for $510M - Fierce Pharma

Bristol Myers, AstraZeneca settle PD-1, CTLA-4 cancer immunotherapy patent suits for $510M Fierce Pharma

Japan cuts Opdivo price in half as costs surge - Fierce Pharma

Japan cuts Opdivo price in half as costs surge Fierce Pharma

Merck to pony up $625M plus Keytruda royalties to settle BMS, Ono patent fight - Fierce Pharma

Merck to pony up $625M plus Keytruda royalties to settle BMS, Ono patent fight Fierce Pharma

Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again - Fierce Pharma

Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again Fierce Pharma

BMS provides figures on Opdivo contribution from Japan in Q2 call - Fierce Pharma

BMS provides figures on Opdivo contribution from Japan in Q2 call Fierce Pharma

Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan - NewswireToday

Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan NewswireToday

Top Ono Pharma Usa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant